Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia

Haematologica

Volumn 92, Issue 3, 2007, Pages 397-400

  Yoshimi, Ayami ^a   Baumann, Irith ^b   Führer, Monika ^c   Bergsträsser, Eva ^d   Göbel, Ulrich ^e   Sykora, Karl Walter ^f   Klingebiel, Thomas ^g   Gross Wieltsch, Ute ^h   Van Den Heuvel Eibrink, Marry M ⁱ   Fischer, Alexandra ^a   Nöllke, Peter ^a   Niemeyer, Charlotte ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h Olgaspital ^*  (Germany)

ⁱ SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Anti thymocyte globulin; Children; Immunosuppressive therapy; Myelodysplastic syndrome; Refractory cytopenia

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; THYMOCYTE ANTIBODY; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; PREDNISONE;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; PEDIATRICS; SURVIVAL RATE; TREATMENT RESPONSE; TRISOMY 8; BLOOD TRANSFUSION; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MORTALITY; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTILYMPHOCYTE SERUM; BLOOD TRANSFUSION; CHILD; COMBINED MODALITY THERAPY; CYCLOSPORINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; LEUKOCYTE COUNT; MYELODYSPLASTIC SYNDROMES; PREDNISONE; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 34247607821     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10683     Document Type: Article

References (15)

1. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myeiomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003;121:758-67.
2. Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003;102:1997-2003.
3. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17:277-82.
4. Barrett J, Saunthararajah Y, Molldrem J Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37:15-29.
5. Smith MA, Smith JG. The occurrence, subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991;15:597-601.
6. Sugawara T, Endo K, Shishido T, Sato A, Kameoka J, Fukuhara O, et al. T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol 1992;41:304-5.
7. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vβ profiles. Br J Haematol 1998;102:1314-22.
8. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137:156-63.
9. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndrome. Leukemia 2004;18:460-5.
10. Cantu Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol 2005; 84:429-33.
11. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005;106: 2102-4.
12. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999;93:2191-5.
13. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-4.
14. Strahm B, Niemeyer CM, Vormoor J, Kremens B, Zind F, Fuehrer M, et al. A reduced-intensity conditioning regimen for children with refractory cytopenia transplanted from an unrelated donors. Leuk Res 2006; 30:S14[Abstract].
15. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002;100:786-90.